CL2011002500A1 - Compuestos derivados 1-alquil-cinolin-4(1h)-ona, moduladores de cb2; procedimiento de preparacion; composicion farmaceutica; y uso para tratar y prevenir el dolor, enfermedades inflamatorias, autoinmunes, entre otras. - Google Patents
Compuestos derivados 1-alquil-cinolin-4(1h)-ona, moduladores de cb2; procedimiento de preparacion; composicion farmaceutica; y uso para tratar y prevenir el dolor, enfermedades inflamatorias, autoinmunes, entre otras.Info
- Publication number
- CL2011002500A1 CL2011002500A1 CL2011002500A CL2011002500A CL2011002500A1 CL 2011002500 A1 CL2011002500 A1 CL 2011002500A1 CL 2011002500 A CL2011002500 A CL 2011002500A CL 2011002500 A CL2011002500 A CL 2011002500A CL 2011002500 A1 CL2011002500 A1 CL 2011002500A1
- Authority
- CL
- Chile
- Prior art keywords
- cinolin
- modulators
- autoimmune
- treat
- alkyl
- Prior art date
Links
- 230000001363 autoimmune Effects 0.000 title 1
- 150000001875 compounds Chemical class 0.000 title 1
- 208000027866 inflammatory disease Diseases 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/26—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
- C07D237/28—Cinnolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Pain & Pain Management (AREA)
- Immunology (AREA)
- Heart & Thoracic Surgery (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Cardiology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pulmonology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Child & Adolescent Psychology (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR0901696A FR2944013B1 (fr) | 2009-04-07 | 2009-04-07 | Derives de 1-alkyl-cinnolin-4(1h)-one substitues,leur preparation et leur application en therapeutique. |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2011002500A1 true CL2011002500A1 (es) | 2012-03-23 |
Family
ID=41051781
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2011002500A CL2011002500A1 (es) | 2009-04-07 | 2011-10-07 | Compuestos derivados 1-alquil-cinolin-4(1h)-ona, moduladores de cb2; procedimiento de preparacion; composicion farmaceutica; y uso para tratar y prevenir el dolor, enfermedades inflamatorias, autoinmunes, entre otras. |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US8420651B2 (es) |
| EP (1) | EP2417111B1 (es) |
| JP (1) | JP5651683B2 (es) |
| KR (1) | KR20120027212A (es) |
| CN (1) | CN102459195A (es) |
| AR (1) | AR076205A1 (es) |
| AU (1) | AU2010233590A1 (es) |
| BR (1) | BRPI1015951A2 (es) |
| CA (1) | CA2757859A1 (es) |
| CL (1) | CL2011002500A1 (es) |
| CO (1) | CO6440578A2 (es) |
| EA (1) | EA201171212A1 (es) |
| FR (1) | FR2944013B1 (es) |
| IL (1) | IL215512A0 (es) |
| MA (1) | MA33250B1 (es) |
| MX (1) | MX2011010650A (es) |
| SG (1) | SG175128A1 (es) |
| TW (1) | TW201040147A (es) |
| UY (1) | UY32548A (es) |
| WO (1) | WO2010116084A1 (es) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021233861A1 (en) | 2020-05-19 | 2021-11-25 | Bayer Aktiengesellschaft | Azabicyclic(thio)amides as fungicidal compounds |
| UY39214A (es) * | 2020-05-19 | 2021-12-31 | Syngenta Crop Protection Ag | Compuestos herbicidas sustituídos con azufre |
| BR112022024413A2 (pt) | 2020-06-10 | 2023-02-07 | Bayer Ag | Heterociclos substituídos com azabiciclila como fungicidas inovadores |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW200306839A (en) * | 2002-02-06 | 2003-12-01 | Novartis Ag | Quinazolinone derivatives and their use as CB agonists |
| WO2009053799A1 (en) * | 2007-10-24 | 2009-04-30 | Glenmark Pharmaceuticals, S.A. | Novel cannabinoid receptor ligands, pharmaceutical compositions containing them, and process for their preparation |
| FR2933697B1 (fr) * | 2008-07-11 | 2010-08-13 | Sanofi Aventis | Derives de 1-benzyl-cinnolin-4-(1h)-one substitues, leur preparation et leur application en therapeutique |
-
2009
- 2009-04-07 FR FR0901696A patent/FR2944013B1/fr active Active
-
2010
- 2010-04-06 SG SG2011073426A patent/SG175128A1/en unknown
- 2010-04-06 KR KR1020117026302A patent/KR20120027212A/ko not_active Withdrawn
- 2010-04-06 CN CN2010800251635A patent/CN102459195A/zh active Pending
- 2010-04-06 TW TW099110626A patent/TW201040147A/zh unknown
- 2010-04-06 CA CA2757859A patent/CA2757859A1/fr not_active Abandoned
- 2010-04-06 EA EA201171212A patent/EA201171212A1/ru unknown
- 2010-04-06 AU AU2010233590A patent/AU2010233590A1/en not_active Abandoned
- 2010-04-06 BR BRPI1015951A patent/BRPI1015951A2/pt not_active Application Discontinuation
- 2010-04-06 AR ARP100101135A patent/AR076205A1/es unknown
- 2010-04-06 EP EP10723208.4A patent/EP2417111B1/fr active Active
- 2010-04-06 MA MA34318A patent/MA33250B1/fr unknown
- 2010-04-06 WO PCT/FR2010/050657 patent/WO2010116084A1/fr not_active Ceased
- 2010-04-06 US US13/262,869 patent/US8420651B2/en not_active Expired - Fee Related
- 2010-04-06 MX MX2011010650A patent/MX2011010650A/es unknown
- 2010-04-06 JP JP2012504054A patent/JP5651683B2/ja not_active Expired - Fee Related
- 2010-04-07 UY UY0001032548A patent/UY32548A/es not_active Application Discontinuation
-
2011
- 2011-10-03 IL IL215512A patent/IL215512A0/en unknown
- 2011-10-07 CL CL2011002500A patent/CL2011002500A1/es unknown
- 2011-10-07 CO CO11132791A patent/CO6440578A2/es not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| TW201040147A (en) | 2010-11-16 |
| MX2011010650A (es) | 2012-01-20 |
| JP5651683B2 (ja) | 2015-01-14 |
| CO6440578A2 (es) | 2012-05-15 |
| EA201171212A1 (ru) | 2012-04-30 |
| JP2012522829A (ja) | 2012-09-27 |
| US8420651B2 (en) | 2013-04-16 |
| MA33250B1 (fr) | 2012-05-02 |
| CN102459195A (zh) | 2012-05-16 |
| EP2417111B1 (fr) | 2014-06-04 |
| UY32548A (es) | 2010-11-30 |
| AR076205A1 (es) | 2011-05-26 |
| WO2010116084A1 (fr) | 2010-10-14 |
| CA2757859A1 (fr) | 2010-10-14 |
| FR2944013B1 (fr) | 2011-07-15 |
| US20120129864A1 (en) | 2012-05-24 |
| EP2417111A1 (fr) | 2012-02-15 |
| KR20120027212A (ko) | 2012-03-21 |
| BRPI1015951A2 (pt) | 2016-04-26 |
| AU2010233590A1 (en) | 2011-11-03 |
| SG175128A1 (en) | 2011-11-28 |
| FR2944013A1 (fr) | 2010-10-08 |
| IL215512A0 (en) | 2011-12-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2007002708A1 (es) | Compuestos derivados de pirrolo[2,3-b]piridina; procedimiento de preparacion; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cancer, caquexia, trastornos inflamatorios, entre otros. | |
| CL2007003832A1 (es) | Compuestos derivados de azaespiro; procedimiento de preparacion; composicion farmaceutica; y su uso para prevenir y tratar ansiedad, trastornos depresivos, entre otras enfermedades. | |
| BRPI0810863A2 (pt) | Uso de hidrolisados de proteína para estabilizar formulações de detergente de metaloprotease. | |
| BRPI0821732A2 (pt) | Formulações de liberação controlada , forma de dosagem sólida, e, uso da formulação de liberação controlada | |
| CL2007002513A1 (es) | Compuestos derivados de isoindolina sustituidos, compuestos intermediarios; composicion farmaceutica; y uso en el tratamiento y prevencion de enfermedades tales como cancer, dolor, degeneracion macular, entre otras. | |
| BRPI0719210A2 (pt) | Uso de compostos espiro-oxindol como agentes terapêuticos | |
| BR112012002331A2 (pt) | composição antiviral, composição farmacêutica e uso de quantidade efetiva de composição farmacêutica | |
| CL2008001921A1 (es) | Compuestos derivados de heterociclos sustituidos; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como ictus, isquemia cerebral, alzheimer, dolor, entre otras. | |
| BRPI0912717A2 (pt) | Composição farmacêutica, e, uso de 5-azacitidina | |
| IL244945B (en) | Cationic lipid, lipid formulations comprising same and use thereof in the preparation of therapeutic agents for delivering to cells | |
| CL2008000690A1 (es) | Compuestos derivados del acido indol-3-propionico; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como hiperlipidemia, hipertension; entre otras. | |
| CL2011002835A1 (es) | Compuestos derivados de 7-aza-espiro[3.5]nonano-7-carboxilatos; procedimiento de preparacion; compuestos intermediarios; composicion farmaceutica; y su uso para tratar dolores agudos o cronicos de tipos neurogeno, asociados a enfermedades inflamatorias, entre otros. | |
| CL2008002893A1 (es) | Compuestos derivados de n-fenil-(piridin-3-il) acetamida sustituidas; composicion farmaceutica; procedimiento de preparacion; y su uso para prevenir o tratar el cancer. | |
| CL2015001731A1 (es) | Compuestos inhibidores de autotaxina; composicion y combinacion farmaceutica; y uso en el tratamiento de enfermedades tales como fibrosis, prurito, cancer, entre otras. | |
| BRPI1011876A2 (pt) | "composição farmacêutica estável e métodos de uso da mesma" | |
| CL2008000875A1 (es) | Compuestos derivados de imidazolidin-2-ona; proceso de obtencion; composicion farmaceutica; y uso en el tratamiento y/o profilaxis de enfermedades tales como dislipidemia, diabetes, enfermedades inflamatorias, entre otras. | |
| ECSP11011459A (es) | Composiciones sublinguales de dexmedetomidina y métodos de uso de ellas | |
| CL2007002199A1 (es) | Compuestos derivados de sulfonil amida, moduladores del receptor cb2; composicion farmaceutica; y su uso para tratar enfermedades inflamatorias y autoinmune. | |
| GT201200313A (es) | 5-fluoro-1h-pirazolopiridinas sustituidas y su uso | |
| BRPI0817200A2 (pt) | composições oftálmicas sólida e uso de compostos para fabricação de medicamento | |
| BR112012003842A2 (pt) | composição farmacêutica, método de formulação e uso da mesma | |
| CL2007002377A1 (es) | Compuestos derivados de quinazolina; procedimiento de preparacion; composicion farmaceutica; y su uso como anticancerigeno. | |
| BRPI0813000A2 (pt) | Composições terapêuticas e uso das mesmas | |
| CL2007002919A1 (es) | Compuestos derivados de pirido[2,3-b]indol, inhibidores de quinasa; procedimiento de preparacion; composicion farmaceutica; y su uso para tratar cancer, entre otras enfermedades. | |
| CL2011000544A1 (es) | Compuestos derivados de benzamida n sustituida por heterociclo, ligandos de los receptores cannabinoides; composicion farmaceutica; y su uso para tratar el dolor, entre otras enfermedades. |